Stay up-to-date on new clinical findings on Acne. View the latest articles, case reports, editorial features, supplements, Podcast episodes and more!
Microneedling is a minimally invasive procedure for treating acne scars which has already been well-established, but it has been reborn in recent years because of innovative findings. It presents many advantages in comparison with other techniques more frequently used such as laser resurfacing and deep chemical peelings; in particular, it consents to achieve good or excellent results with a minimal time (2-3 days) of recovery and rare complications, even in dark phototypes.1,2
One of the key characteristics of acne is post-inflammatory hyperpigmentation and is most noticeable in darker skin tones. It is also important to point out that keloidal or hypertrophic scarring may result and should be considered when treating patients.
Here we can appreciate the erythema of inflammatory papules in lighter skin tones and the brown coloration of inflammatory papules mimicking post-inflammatory hyperpigmentation in darker skin tones.
Do not pop, rather pick a therapeutic strategy from the wide array of new….oh wait, nevermind. The world of acne treatment R&D is unfortunately shrinking as payors pick away at the medical necessity of managing the most common inflammatory skin disease. Like Marty McFly fading in that famous family photo, the spotlight on acne is shifting, enough to make Dr. Pimple Punisher Dr. Hilary Baldwin pick up a bottle of Prozac. But all hope is not lost.
Join JDD Podcast host Dr. Adam Friedman as he and Dr. Baldwin scour the therapeutic landscape and take a sharp left into the over the counter space to review accessible options to manage both the today and tomorrow of Acne Vulgaris, the symbiosis between RX and OTC to address barrier dysfunction, scarring and hyperpigmentation.
Delays in Medical Care Among Skin of Color Melanoma Patients: A Population-Based Study
JDD Re:View With Dr. Beer
JDD Re:View With Dr. Beer
Rapid Clearance of Lichen Planus With Topical Tapinarof
© 2026 Journal of Drugs in Dermatology. All Rights Reserved. JDD, a peer-reviewed, MEDLINE®/PubMed® indexed journal, offers the dermatology community strong content of utmost quality and relevance on drugs, devices, and methods.
